Stay updated with breaking news from Johan Dalsgaard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GOTHENBURG, Sweden, March 4, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2
The new AT2R agonist C106, with patent protection to 2041, is ready to enter a phase 1 trial Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022 R&D-day
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...